SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 8/22/2017 12:58:10 PM - Followers: 38 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 3rd quarter of 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid to late 2017. Patent protection for their neutral lipid delivery system has been allowed.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 9+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.


Zack's rating now equals hold.

                        
 
 
 
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2949   Here is another reason PN has to delist SJSTOCKSHARK 08/22/17 12:58:10 PM
#2948   Yes Brett, a HUGE apology to you, Pat, BPTH2008 08/22/17 11:35:04 AM
#2947   DAY 7 UNTIL DELISTING! DO YOU KNOW WHERE SJSTOCKSHARK 08/22/17 11:15:10 AM
#2946   PN is currently trying to blame everyone else Brettj 08/22/17 10:47:40 AM
#2945   Never underestimate PN's ineptitude and ability to tear Pat Torney 08/22/17 10:27:52 AM
#2944   Yes GP, it will still be tradeable. Oddly BPTH2008 08/21/17 11:26:52 PM
#2943   There are plenty of reasons to be excited BPTH2008 08/21/17 11:19:18 PM
#2942   Backup plan? Their 1st plan has been a dmoffat 08/21/17 08:55:47 PM
#2941   GP, Yes but now they also have a SJSTOCKSHARK 08/21/17 07:37:57 PM
#2940   I read that statement to say that BPTH Gpheart2016 08/21/17 06:32:58 PM
#2939   August 29, 2017 SJSTOCKSHARK 08/21/17 03:01:02 PM
#2938   SJS, I have been a little out of too simple 08/21/17 02:39:01 PM
#2937   Question: what happens after delisting? Will Gpheart2016 08/21/17 01:31:27 PM
#2936   DAY 8 UNTIL DELISTING! DO YOU KNOW SJSTOCKSHARK 08/21/17 01:05:07 PM
#2935   PN should send us both thank you letters! dmoffat 08/21/17 08:36:03 AM
#2934   Moffat, As I have repeatedly posted I have SJSTOCKSHARK 08/20/17 08:59:31 PM
#2933   Word, thanks for posting the positive thoughts and Optimator 08/19/17 07:00:06 PM
#2932   The board members walking away and stating leadership dmoffat 08/19/17 06:36:06 PM
#2931   I would not see that as you eating wordlender 08/19/17 03:02:22 PM
#2930   Word UP, There are many more positives about SJSTOCKSHARK 08/19/17 01:04:59 AM
#2929   SJ, that is the bear case. It is wordlender 08/18/17 10:13:02 PM
#2928   PB, Long term BPTH prospects? To quote Super SJSTOCKSHARK 08/17/17 02:03:12 PM
#2927   Hey everybody... I have just been a consumer PoorBoy91 08/17/17 01:03:51 PM
#2926   I wonder what kind of board member would too simple 08/16/17 09:32:44 PM
#2925   LOL disregard my previous message BPTH2008 08/16/17 08:45:54 PM
#2924   I was confused about this 180 days... so BPTH2008 08/16/17 08:45:23 PM
#2923   Agree with you 100% PN has ruined this BPTH2008 08/16/17 08:41:28 PM
#2922   Good News? dmoffat 08/16/17 08:41:26 PM
#2921   Actually no good news. I believe I am SJSTOCKSHARK 08/16/17 08:25:38 PM
#2920   Agreed 180 days of more time is very SJSTOCKSHARK 08/16/17 07:57:00 PM
#2919   Finally, something is happening ( if I read too simple 08/16/17 07:07:41 PM
#2918   So it seems like they are saying the dmoffat 08/16/17 06:43:30 PM
#2917   Big news! SJSTOCKSHARK 08/16/17 05:45:04 PM
#2916   Transcript of conference call: wordlender 08/16/17 10:16:22 AM
#2915   SJ, I agree completely with you and Too Snug9 08/11/17 10:20:39 AM
#2914   There is no chance of PN being fired. SJSTOCKSHARK 08/10/17 07:30:02 PM
#2913   Anybody else at any other job performing this dmoffat 08/10/17 07:03:24 PM
#2912   Snug and SJS , agree with both of too simple 08/10/17 05:38:36 PM
#2911   Snug, I agree with you. PN has mismanaged SJSTOCKSHARK 08/10/17 05:19:06 PM
#2910   SJ, I am frustrated that BPTH is still Snug9 08/10/17 03:50:23 PM
#2909   Without actually seeing his statement and reading the Snug9 08/10/17 03:35:06 PM
#2908   Moffat, Here is the info. regarding short selling SJSTOCKSHARK 08/10/17 02:05:24 PM
#2907   Does anyone think this stock will start to underdogwins 08/10/17 01:38:07 PM
#2906   Who knows the official short options for a dmoffat 08/10/17 11:14:11 AM
#2905   Brettj, They claim to have enough cash to SJSTOCKSHARK 08/10/17 10:53:07 AM
#2904   The company is also on track to be Brettj 08/10/17 10:14:21 AM
#2903   The company is on track to announce results SJSTOCKSHARK 08/10/17 09:14:50 AM
#2902   I doubt you'll find anything in that document Brettj 08/10/17 07:29:06 AM
#2901   Just when you thought it was ugly, it iloveu2 08/09/17 09:02:26 PM
#2900   Peter Nielsen makes $8000 a week and we dmoffat 08/09/17 06:09:03 PM
PostSubject